Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Recommendation of “Hold” from Analysts

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) has earned an average rating of “Hold” from the seven ratings firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $10.80.

Several equities analysts recently weighed in on the company. Weiss Ratings lowered Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Xeris Biopharma in a research note on Monday, March 2nd. Finally, Wall Street Zen upgraded Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 7th.

Insider Activity at Xeris Biopharma

In other Xeris Biopharma news, insider Beth Hecht sold 16,667 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $6.23, for a total transaction of $103,835.41. Following the completion of the sale, the insider directly owned 1,193,173 shares in the company, valued at approximately $7,433,467.79. The trade was a 1.38% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director James Aloysius Brady sold 10,834 shares of the business’s stock in a transaction that occurred on Monday, March 30th. The stock was sold at an average price of $5.54, for a total value of $60,020.36. Following the sale, the director owned 89,166 shares of the company’s stock, valued at approximately $493,979.64. This trade represents a 10.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 60,835 shares of company stock valued at $367,860. 4.56% of the stock is owned by company insiders.

Institutional Investors Weigh In On Xeris Biopharma

Several large investors have recently bought and sold shares of XERS. Royal Bank of Canada increased its stake in Xeris Biopharma by 1,411.2% during the 1st quarter. Royal Bank of Canada now owns 213,084 shares of the company’s stock worth $1,170,000 after buying an additional 198,984 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Xeris Biopharma by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock worth $461,000 after buying an additional 3,594 shares in the last quarter. Millennium Management LLC increased its stake in Xeris Biopharma by 19.0% during the 1st quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock worth $12,726,000 after buying an additional 369,420 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in Xeris Biopharma by 75.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after buying an additional 1,199,435 shares in the last quarter. Finally, Caxton Associates LLP purchased a new stake in Xeris Biopharma during the 1st quarter worth approximately $170,000. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

Xeris Biopharma Price Performance

Shares of Xeris Biopharma stock opened at $6.01 on Tuesday. The company has a quick ratio of 1.50, a current ratio of 2.12 and a debt-to-equity ratio of 17.00. Xeris Biopharma has a twelve month low of $4.30 and a twelve month high of $10.08. The business has a 50-day moving average price of $5.93 and a 200 day moving average price of $6.81. The firm has a market cap of $1.04 billion, a PE ratio of 100.17 and a beta of 0.85.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.01 earnings per share for the quarter. Xeris Biopharma had a return on equity of 735.00% and a net margin of 3.81%.The firm had revenue of $83.13 million during the quarter, compared to analyst estimates of $79.83 million. Sell-side analysts predict that Xeris Biopharma will post 0.12 earnings per share for the current fiscal year.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.